Literature DB >> 9564171

Mechanisms and functions of vitamin D.

H F DeLuca1, C Zierold.   

Abstract

The vitamin D hormone, 1,25-dihydroxyvitamin D3, functions by way of a nuclear receptor (vitamin D receptor [VDR]) in a manner analogous to the other members of the steroid-thyroid hormone superfamily. Although the vitamin D receptor has been cloned, its three-dimensional structure remains unknown. The VDR binds to the direct repeat response elements called DR-3 in the promoter region of target genes to stimulate or suppress transcription of those genes encoding for proteins that carry out a wide variety of functions. The binding of the VDR to a DR-3 requires the presence of its ligand and a companion protein, namely the RXR group of retinoid receptors. The RXR binds to the 5' arm of the response element while the VDR binds to the 3' arm. In addition, the transcription factor TFIIB has been shown to bind VDR but there is currently no evidence that a co-repressor or co-activator of VDR is also involved. Phosphorylation of VDR in the transcription complex occurs as does bending of the DNA prior to the initiation or suppression of transcription. As VDR has been detected in cells not previously thought to be target organs, scientists continue to discover new functions of vitamin D. Among these new functions are those noted in the immune system. Experiments in mice have illustrated that the autoimmune diseases of multiple sclerosis and rheumatoid arthritis can be successfully treated with the vitamin D hormone and its analogs. New experiments illustrating the use of the vitamin D hormone and its analogs in suppressing transplant rejection indicate that these compounds may be superior to cyclosporin and may not have the side effects attributed to the cyclosporin immunosuppression therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564171     DOI: 10.1111/j.1753-4887.1998.tb01686.x

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  45 in total

1.  Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons.

Authors:  L D Brewer; V Thibault; K C Chen; M C Langub; P W Landfield; N M Porter
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

2.  Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands.

Authors:  G Tocchini-Valentini; N Rochel; J M Wurtz; A Mitschler; D Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

3.  AT1R blockade in adverse milieus: role of SMRT and corepressor complexes.

Authors:  Tejinder Singh; Kamesh Ayasolla; Partab Rai; Nirupama Chandel; Shabirul Haque; Rivka Lederman; Mohammad Husain; Vasupradha Vethantham; Amrita Chawla; Himanshu Vashistha; Moin A Saleem; Guohua Ding; Praveen N Chander; Ashwani Malhotra; Leonard G Meggs; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-17

4.  Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency.

Authors:  T Diamond; Y K Wong; T Golombick
Journal:  Osteoporos Int       Date:  2012-03-16       Impact factor: 4.507

5.  27-Oxygenation of C27-sterols and 25-hydroxylation of vitamin D3 in kidney: cloning, structure and expression of pig kidney CYP27A.

Authors:  H Postlind; F Hosseinpour; M Norlin; K Wikvall
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 6.  Progesterone and vitamin d hormone as a biologic treatment of traumatic brain injury in the aged.

Authors:  Donald G Stein; Milos M Cekic
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

7.  HOTAIR but not ANRIL long non-coding RNA contributes to the pathogenesis of multiple sclerosis.

Authors:  Majid Pahlevan Kakhki; Abbas Nikravesh; Zeinab Shirvani Farsani; Mohammad Ali Sahraian; Mehrdad Behmanesh
Journal:  Immunology       Date:  2017-11-16       Impact factor: 7.397

8.  Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells.

Authors:  T Tanaka; B L Dancheck; L C Trifiletti; R E Birnkrant; B J Taylor; S H Garfield; U Thorgeirsson; L M De Luca
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  Genome-wide association study of circulating vitamin D levels.

Authors:  Jiyoung Ahn; Kai Yu; Rachael Stolzenberg-Solomon; K Claire Simon; Marjorie L McCullough; Lisa Gallicchio; Eric J Jacobs; Alberto Ascherio; Kathy Helzlsouer; Kevin B Jacobs; Qizhai Li; Stephanie J Weinstein; Mark Purdue; Jarmo Virtamo; Ronald Horst; William Wheeler; Stephen Chanock; David J Hunter; Richard B Hayes; Peter Kraft; Demetrius Albanes
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

10.  Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.

Authors:  Jason Gee; Howard Bailey; Kyungmann Kim; Jill Kolesar; Tom Havighurst; Kendra D Tutsch; William See; Michael B Cohen; Nick Street; Leon Levan; David Jarrard; George Wilding
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.